Prognostic values of microRNA-130 family expression in patients with cancer: a meta-analysis and database test

Table 3 Main results of pooled HRs in the meta-analysis

Comparisons (miRNA-130 family)	Heterogeneity test			Summary HR (95% CI)	Hypothesis test		Studies
Comparisons (miRNA-130 family)	Q	P	I² (%)	Summary HR (95% CI)	Z	P	Studies
miRNA-130a
OS
Total	22.74	0.01	56	1.58 (1.21,2.06)	3.34	< 0.001	11
Tissue	21.28	0.01	62	1.54 (1.11,2.14)	2.60	0.009	9
Serum	1.00	0.32	0	1.65 (1.14,2.38)	2.65	0.008	2
Subgroup differences	0.07	0.79	0
Cancer subtypes
Gastric cancer	1.94	0.38	0	1.81 (1.34,2.45)	3.83	< 0.001	3
Other cancers	18.30	0.01	62	1.46 (1.01,2.08)	2.11	0.03	8
DFS
Total	24.08	< 0.01	79	1.35 (0.72,2.52)	0.93	0.35	6
Tissue	23.91	< 0.01	83	1.32 (0.52,3.40)	0.58	0.56	5
Serum	–	–	–	1.38 (0.99,1.91)	0.21	0.83	1
Subgroup differences	0.01	0.94	0
miRNA-130b
OS
Total	60.10	< 0.01	77	1.95 (1.47,2.59)	4.65	< 0.001	15
Tissue	44.46	< 0.01	75	2.01 (1.39,2.91)	3.71	< 0.001	12
Serum	15.50	< 0.01	87	1.96 (1.09,3.54)	2.23	0.03	3
Subgroup differences	0.01	0.94	0
Ethnicity
Asian	12.15	0.06	51	2.55 (1.77,3.69)	5.00	< 0.001	7
Caucasian	23.95	< 0.01	71	1.47 (1.08,1.99)	2.45	0.01	8
Cancer subtypes
HCC	10.59	0.01	72	2.43 (1.28,4.63)	8.24	0.004	4
Other cancers	30.80	< 0.01	74	1.75 (1.30,2.37)	3.67	< 0.001	11
DFS/PFS
Total	7.38	0.12	46	1.53 (1.31,1.77)	5.53	< 0.001	5
Tissue	2.48	0.29	19	1.98 (1.50,2.62)	4.85	< 0.001	3
Serum	0.03	0.86	0	1.37 (1.15,1.64)	3.46	< 0.001	2
Subgroup differences	4.87	0.03	79.5
Cancer subtypes
HCC (DFS)	2.48	0.29	19	1.98 (1.50,2.62)	4.85	< 0.001	3
Other cancers	0.03	0.86	0	1.37 (1.15,1.64)	3.46	< 0.001	2

OS, overall survival; DFS, disease free survival; PFS, progressive free survival; HCC, hepatocellular carcinoma

ISSN: 1479-5876